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Abstract
Background: The v-erbA oncogene, carried by the Avian Erythroblastosis Virus, derives from the
c-erbAα proto-oncogene that encodes the nuclear receptor for triiodothyronine (T3R). v-ErbA
transforms erythroid progenitors in vitro by blocking their differentiation, supposedly by
interference with T3R and RAR (Retinoic Acid Receptor). However, v-ErbA target genes involved
in its transforming activity still remain to be identified.
Results: By using Serial Analysis of Gene Expression (SAGE), we identified 110 genes deregulated
by v-ErbA and potentially implicated in the transformation process. Bioinformatic analysis of
promoter sequence and transcriptional assays point out a potential role of c-Myb in the v-ErbA
effect. Furthermore, grouping of newly identified target genes by function revealed both expected
(chromatin/transcription) and unexpected (protein metabolism) functions potentially deregulated
by v-ErbA. We then focused our study on 15 of the new v-ErbA target genes and demonstrated by
real time PCR that in majority their expression was activated neither by T3, nor RA, nor during
differentiation. This was unexpected based upon the previously known role of v-ErbA.
Conclusion: This paper suggests the involvement of a wealth of new unanticipated mechanisms of
v-ErbA action.
Background
The Avian Erythroblastosis Virus (AEV) induces erythro-
leukemia and sarcomas in chickens [1]. This retrovirus
also transforms erythroid progenitors and chicken
embryo fibroblasts in vitro. The AEV carries two viral onco-
genes in its genome, v-erbA and v-erbB. The expression of
v-ErbA alone is sufficient to block differentiation of eryth-
rocytic progenitors in vitro and  in vivo [2,3].  v-erbA  is
derived from the c-erbA proto-oncogene, which encodes
the alpha form of the nuclear receptor for the thyroid hor-
mone triiodothyronine (T3Rα) [4]. This oncogene is
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expressed as a gag-v-ErbA fusion protein that binds to the
DNA but does not bind the hormone T3 [4].
The most widely accepted hypothesis is that v-ErbA antag-
onizes ligand-dependent activation by T3R, to silence T3
responsive genes even in the presence of T3 [5-7]. The
finding that overexpression of T3R and addition of ligand
can overcome the blockade of differentiation induced by
v-ErbA supports this assumption [8]. Moreover, it was
shown that v-ErbA also inhibits transcription mediated by
ligand-activated Retinoic Acid Receptors (RAR) and that
this inhibition is also of importance since a non-trans-
forming point mutant for v-ErbA, S61G, is unable to block
transcription mediated by RAR [9].
It has therefore been proposed that the v-ErbA oncopro-
tein represses genes that are normally upregulated by T3
and Retinoic Acid (RA) and that are upregulated during
the differentiation process [5,9]. Nevertheless, this
hypothesis remains speculative as long as v-ErbA target
genes harboring those properties are not found. So far,
four v-ErbA target genes have been described: Carbonic
anhydrase II (CAII), erythrocyte anion transporter (Band3),
integrin α2 subunit (VLA2) and δ-aminolevulinate synthase
(ALA-S) [10-12]. It has been demonstrated only in the
case of the CAII gene that v-ErbA acts as a dominant neg-
ative of T3R by occluding the DNA response element and
ablating the T3 mediated activation [13]. In contrast, the
expression of Band3, ALA-S and VLA2 genes is not control-
led by T3 suggesting that v-ErbA may act independently of
T3R [10,11]. This is consistent with the observation that v-
ErbA also interferes with pathways controlled by other
transcription factors [9,14]. Furthermore, functional stud-
ies have clearly demonstrated that the repression of Band3
and CAII by v-ErbA is not sufficient to account for the dif-
ferentiation blocking ability of this oncoprotein [15].
Therefore, the precise mechanisms of v-ErbA action
remain unclear and the identification of relevant v-ErbA
target genes represents a mandatory step in its under-
standing. We thus decided to use a large-scale transcrip-
tomic approach by SAGE (Serial Analysis of Gene
Expression) to identify v-ErbA target genes involved in its
transforming activity. One of the most important advan-
tages of this technique is the possibility to obtain a com-
prehensive view of all the transcripts present in a cell
population at a given time point, allowing the discovery
of new genes [16]. We have used a cellular model of nor-
mal immature erythroid progenitors called T2ECs (TGF-α
TGF-β induced erythrocytic cells) [17] which are the natu-
ral target cells of v-ErbA. In order to identify v-ErbA target
genes responsible for the transformation process induced
by v-ErbA, we have compared the transcriptome of T2ECs
expressing an oncogenic form of v-ErbA with the tran-
scriptome of T2ECs expressing the S61G mutant of v-ErbA
[9,18]. This mutant, which carries a glycine in the DNA
binding domain, is equivalent to the c-erbA sequence at
this position, and is defective in its ability to inhibit differ-
entiation and to induce erythroid transformation [18].
Thus, the comparison between the transcriptome of cells
expressing either the transforming form of v-ErbA or the
S61G mutant of v-ErbA allowed us to generate a list of 110
differentially expressed genes between these two condi-
tions, 15 of which were observed to be repressed by v-
ErbA by real-time PCR on different cell populations. A
bioinformatic approach revealed the presence of c-Myb
binding sites in the promoters of v-ErbA target genes. The
identification of these sites coupled with a functional c-
Myb transcriptional assay point out a putative role of c-
Myb in the transformation process. Unexpectedly, the glo-
bal analysis of gene functions reveals that two main cellu-
lar functions, protein metabolism and chromatin
structure/transcriptional regulation, could be deregulated
by v-ErbA. We further show here that the expression of
most newly identified v-ErbA target genes is neither under
the control of T3 nor RA, nor upregulated during differen-
tiation. In conclusion, we have identified several new v-
ErbA target genes unknown up to now and we present evi-
dence that v-erbA oncogene action involves new unantici-
pated mechanisms of action.
Results
Potential v-ErbA target genes identified by SAGE analysis
We constructed two SAGE libraries of T2ECs infected
either with the XJ12 retrovirus which expresses the onco-
genic form of v-erbA  (VA) or with the S61G retrovirus
which expresses a non-transforming form of v-erbA
(NTVA) in order to identify v-ErbA target genes responsi-
ble for transformation. 59391 tags were obtained from the
VA library and 37347 tags from the NTVA library. We
obtained 5764 different tags appearing more than once in
the VA library and 4153 different tags in the NTVA library.
The comparison of these two SAGE libraries revealed 110
differentially expressed genes between these two condi-
tions with a p-value adjusted for multiple testing < 0.1
(Figure 1). 44 of them were up-regulated and 66 down-
regulated in T2ECs expressing the transforming form of v-
ErbA (VA) as compared to T2ECs expressing the non-
transforming form of v-ErbA (NTVA). In view of these
results, v-ErbA seems to have mostly a repressive action on
gene transcription because it represses more genes than it
activates. This essentially repressive action of v-ErbA on
gene expression was further confirmed by real-time PCR
(see below). However, the vast majority of tags were
equally abundant in these two libraries, suggesting that
the switch from a normal state toward a pathological state
involves a very limited number of genes.BMC Genomics 2007, 8:390 http://www.biomedcentral.com/1471-2164/8/390
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Presence of c-Myb binding sites in the promoters of v-ErbA 
repressed target genes
In order to investigate the molecular mechanisms by
which v-ErbA regulates gene expression, we next searched
for common motifs in the promoters of the v-ErbA target
genes identified by SAGE. For that purpose, we first iden-
tified SAGE tags by using Identitag [19] and then aligned
the corresponding transcripts on the chicken genome. It
has been demonstrated for CAII that v-ErbA binds to sev-
eral domains in the proximal promoter sequence, up to
600 bp of the transcription start site (TSS) [20]. Moreover,
it has been demonstrated that the position of transcrip-
tion factor binding sites often lie within a few kb 5' of the
basal promoter [21]. We therefore decided to consider as
promoter regions 3 kbp 5' of the TSS and 1 kbp 3' of the
TSS.
We obtained 31 promoter sequences from genes that
appeared as being repressed by the transforming form of
v-ErbA by SAGE and 21 sequences from genes that
appeared as being activated by the same form of v-ErbA
compared to the non transforming form of v-ErbA. We
first searched for known v-ErbA response elements [22-
25]. All the nuclear receptors of the c-ErbA family recog-
nize derivatives of the same hexameric DNA core motif 5'-
AGGTCA-3' [25]. We found response elements based
upon this motif only in 3 promoters. The response ele-
ment PAL-0 (AGGTCATGACCT) is present in RPL11 and
Comparative gene expression levels between VA and NTVA libraries Figure 1
Comparative gene expression levels between VA and NTVA libraries. The occurrence number of each tag (normal-
ized in tag per million) in VA (X axis) and NTVA (Y axis) libraries is represented on a logarithmic scale. Each point can repre-
sent one or more tags. Colour-coding is based on a statistical analysis (Z test [47]), adjusted for multiple testing according to 
the method proposed by Benjamini and Hochberg [48]. Black dots represent the 110 tags having an adjusted p-value < 0.1. 
These tags correspond to genes that are significantly differentially expressed between these 2 conditions. Among these genes, 
44 are up-regulated (the corresponding points are located below the first bisecting line) and 66 are down-regulated (the corre-
sponding points are located above the first bisecting line) in T2ECs expressing the transforming form of v-ErbA as compared to 
T2ECs expressing the non-transforming form of v-ErbA. The gray dots represent all the other tags.BMC Genomics 2007, 8:390 http://www.biomedcentral.com/1471-2164/8/390
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Succinate  promoters while the response element DR-4
(AGGTCAnnnnAGGTCA) is present in RPS3 and Succinate
promoters (data not shown). It has been demonstrated
that T3R binds preferentially and rather specifically to T3
response element (TRE) of the DR-4 structure [25,26]. The
palindromic element without a spacer (PAL-0) is not spe-
cific to T3R since it works efficiently as a retinoic acid
responsive element (RARE) [25,26]. However, despite the
presence of the T3 response element in RPS3 promoter,
the expression of this gene did not vary in response to T3
(see below). To conclude, out of 52 promoters analyzed,
we have only identified 3 promoters with known response
element for T3R, RAR and v-ErbA. It is conceivable that
the 4 kb region considered is not sufficient since binding
sites that would be more distal to the TSS will be missed
by this approach. Furthermore, it is also obvious that the
simple presence of a transcription factor binding site
(TFBS) does not imply an activity of that transcription fac-
tor. Finally, even if the protein binds the TFBS, we cannot
be informed about the direction of the regulation (i.e.
activation or inhibition). Nevertheless, we have found few
v-ErbA/T3R/RAR response elements in this region that is
in accordance with the experimental assessment of the
expression pattern of newly identified v-ErbA target genes
under the influence of T3R and RAR (see below).
Since very few v-ErbA target gene promoters contain a
known response element for T3R, RAR and v-ErbA, we
searched for motifs that could be enriched in these pro-
moters, without any a priori on these motifs except its
minimal length. For this purpose, we used an implemen-
tation of an extended FAVST (Finite Automata-based VST
construction) algorithm [27]. This allowed us to identify
a c-Myb binding site (CAGTTA) [28] as a signature motif
of many newly identified v-ErbA repressed target genes
compared with v-ErbA activated target genes. Indeed, 64%
of v-ErbA repressed genes have the c-Myb binding motif in
their promoter sequences (Figure 2). Among the v-ErbA
target genes that contain at least one c-Myb binding site in
their promoter region, several have been validated as v-
ErbA repressed target genes by real-time RT-PCR (see
below). This suggests a potential role for c-Myb in the v-
ErbA induced transformation.
To determine the role of c-Myb in this transformation
process, the expression level of this gene was quantified by
real-time PCR in T2ECs expressing the transforming form
of v-ErbA (VA) compared to T2ECs expressing the non-
transforming form of v-ErbA (NTVA) in five independent
experiments (Figure 3A). The expression of c-myb did not
vary between these two conditions. Similarly, we observed
that the expression level of the c-Myb protein was also not
modified in cells expressing v-ErbA compared with cells
expressing the non-transforming S61G mutant (Figure
3B). Although the level of c-Myb protein is increased by
both forms of v-ErbA compared with non-infected T2ECs,
these results suggest that this upregulation of c-Myb by v-
ErbA is not sufficient to induce a transformation process.
Finally, we used a gene reporter assay to test the ability of
v-ErbA to transactivate c-Myb. We transfected T2ECs with
a reporter plasmid in which five strong c-Myb binding
sites were placed upstream of a simple TATA box and a
luciferase cDNA [29]. This reporter plasmid (EW5) was
clearly active in T2ECs (Figure 3C), which express c-Myb
(see above). Moreover, a 1.7-fold increase of luciferase
activity was seen with the transforming form of v-ErbA
(VA) compared to the S61G mutant for v-ErbA (NTVA). A
control reporter gene containing five mutant c-Myb bind-
ing sites (EM5) was much less active in these cells, and its
activity was unaffected by the different forms of v-ErbA. It
is thus conceivable that the c-Myb binding to a real pro-
moter, presenting a higher complexity with several tran-
scription factor binding sites, silencers and enhancers,
could result in an inhibition of gene expression controlled
by such a promoter. Therefore, although the direction of
the functional interaction was unexpected (activation ver-
sus repression), these data nevertheless demonstrate that
v-ErbA can indeed functionally interact directly or indi-
rectly with the transcriptional activity of endogenous c-
Myb in T2ECs.
v-ErbA mostly affects chromatin/transcription and protein 
metabolism genes
We clustered the newly identified v-ErbA target genes
according to the cellular function encoded by their corre-
sponding proteins (Figure 4). Each protein may be impli-
cated in different functions i.e. a protein may belong to
different groups.
The use of functional annotations (mainly Gene Ontol-
ogy (GO) annotations) allowed us to find that many v-
ErbA repressed target genes are involved in two main cel-
lular functions: chromatin structure/transcriptional regu-
lation and protein metabolism.
The remodelling of chromatin and transcription regula-
tion constituted a cellular function that was expected to be
deregulated by v-ErbA. Indeed, v-ErbA represses transcrip-
tion via association with corepressors such as NCoR and
SMRT [30]. The corepressors, in turn, recruit histone
deacetylase (HDAC) containing complexes that stabilize
repressive chromatin structure to assure efficient silencing
of downstream genes [31,32].
Protein metabolism is the most represented and the most
unanticipated category. It suggests the importance of the
translation and the protein degradation processes during
transformation. Among the genes that are implicated in
protein synthesis, we have observed an important numberBMC Genomics 2007, 8:390 http://www.biomedcentral.com/1471-2164/8/390
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Position of the c-Myb binding motif in the promoter sequences of v-ErbA target genes Figure 2
Position of the c-Myb binding motif in the promoter sequences of v-ErbA target genes. The position of the c-Myb 
binding motif (CAGTTA) is represented as grey boxes in the promoter regions of v-ErbA repressed genes containing at least 
one such motif (i.e. 64% of the v-ErbA repressed genes identified by SAGE). The 4 kb sequence flanking the transcription start 
site (TSS, shown at position 3000) are displayed. The following parameters were used for extracting this motif: minimal motif 
size: 5; maximum number of examples in the negative (v-ErbA activated) set: 5; minimum number of examples in the positive 
(v-ErbA repressed) set: 20. Arrowheads indicate the genes that have been validated as v-ErbA repressed genes by real time 
PCR.
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Expression level of c-Myb in T2ECs expressing v-ErbA or the S61G form of v-ErbA Figure 3
Expression level of c-Myb in T2ECs expressing v-ErbA or the S61G form of v-ErbA. 3A – Effect of v-ErbA on the 
expression level of the c-myb gene. Total RNA was extracted from T2ECs expressing either the oncogenic form or the non-
transforming form of v-erbA. A reverse transcription and real-time PCR analysis were performed to quantify the expression 
level of c-myb gene. The fold variation is represented as VA/NTVA ratio and corresponds to a decrease or an increase of the c-
myb mRNA in T2ECs expressing the transforming form of v-ErbA (VA) in comparison with T2ECs expressing the non-trans-
forming form of v-ErbA (NTVA). The grey bars represent a mean of ratio calculated using the three reference genes T-Complex 
1, hnRNP and ATP synthase subunit B1. The hatched bar is the mean of mRNA accumulation in the five independent experiments. 
3B – Effect of v-ErbA on the expression level of the c-Myb protein. T2ECs were either left non-infected (T2ECs), infected by a 
retrovirus carrying the wild type v-ErbA (VA) or carrying the point-mutated form of v-ErbA, S61G (NTVA). Protein extracts 
(30 µg) were analyzed and two separate western blots were probed with an anti-c-Myb or anti-GAPDH antibody. 3C – Differ-
ent effects of v-ErbA and S61G on c-Myb responsive transcription. T2ECs were transfected with reporter plasmids containing 
either five wild-type (EW5) or mutant (EM5) Myb-binding sites upstream of a simple TATA box. Each reporter was tested with 
a vector expressing or not the transforming form of v-ErbA (VA) or a vector expressing the S61G mutant for v-ErbA (NTVA) 
and the β-Galactosidase expressing plasmid. Twenty-four hours after transfection, the cells were analyzed for luciferase activ-
ity, which reflects the ability of the c-Myb protein to regulate the gene expression. Luciferase activities were normalized by 
using β-Gal expression as an internal control. Luciferase activity in the presence of EW5 and the transforming form of v-ErbA 
was assigned to a value of 100%. The pGL2 plasmid transfected in normal T2ECs represents the negative control (vector which 
does not contain any binding sites upstream the luciferase coding region). Data are average of two (EM5 and pGL2) to three 
experiments (EW5) and error bars indicate maximum and minimum values of different sets of data points.
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Cellular functions of genes repressed by the transforming form of v-ErbA Figure 4
Cellular functions of genes repressed by the transforming form of v-ErbA. This figure shows the two main cellular 
functions of genes repressed by the transforming form of v-ErbA. For each function, the annotations of all genes harbouring 
this function is represented (only the more precise term in the Gene Ontology and only the annotations concerning more than 
one half of genes are represented. GO MF: Gene Ontology molecular function, GO BP: Gene Ontology biological process, SP 
KW: Swissprot keyword, KEGG PW: KEGG pathway). A black square in the intersection of one line (one gene) and one col-
umn (one annotation) imply that the corresponding gene has the corresponding annotation. The gene names written in bold 
correspond to genes for which the differential expression has been confirmed by real-time PCR.
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of ribosomal proteins. However, the expression of all
ribosomal proteins is not affected by v-ErbA since a vast
number of genes encoding ribosomal proteins (RPL3,
RPL7,  RPL12,  RPL24,  RPL29,  RPS4,  RPS6,  RPS10  and
RPS13) was shown not to vary by real time PCR (data not
shown). This suggests that only a specific subset of some
ribosomal proteins is affected by v-ErbA.
The other genes down-regulated by v-ErbA, which are not
implicated in these two cellular functions, are either
implicated in different functions or their functions are
unknown. Among these genes, stem cell antigen 2 (sca2)
and transforming growth factor-β1 (TGF-β1) encode pro-
teins that are involved in the regulation of intracellular
signalling pathways. Indeed, we have observed that v-
ErbA is able to modulate the TGF-β signalling pathway in
T2ECs (Gonin-Giraud et al., submitted). These data sug-
gest a role for v-ErbA in intracellular signalling pathways
in agreement with its cytoplasmic localisation [33].
In contrast, the candidate genes whose expression is up-
regulated by v-ErbA are fewer and are involved in a greater
variety of functions, such as sodium-calcium exchange,
chaperone activity, nuclear transport and others.
15 v-ErbA target genes validated by real time-PCR on 
multiple experiments
The relative expression levels of v-ErbA target genes iden-
tified by SAGE were quantified by real-time PCR in T2ECs
expressing the transforming form of v-ErbA (VA) com-
pared to T2ECs expressing the non-transforming form of
v-ErbA (NTVA) in five independent experiments. We
selected 40 candidates and used the sequence of the corre-
sponding transcripts in order to design PCR primers. The
differential expression between VA and NTVA conditions
has been observed for 15 of them (Figure 5). All these
genes are repressed by the transforming form of v-ErbA
compared to the non-transforming one. The majority of
these genes are involved in protein synthesis, like ribos-
omal proteins (RPS3, RPS3a, RPS9, RPL13) and transla-
tion initiation and elongation factors (eIF2B2, eEF1α1).
We observed that genes were not repressed at the same
fold variation in the five different experiments. This can be
due to a biological variability between different cultures,
as we showed in our previous analysis of the transcrip-
tome of T2ECs in a self-renewal or in a differentiation
state [34]. By contrast, the expression of the 25 candidates,
which have not been confirmed by real-time PCR, could
be explained by different hypothesis (multiple or errone-
ous identification, variability in gene expression, specific
gene variations during the culture that was used for pre-
paring SAGE mRNAs, etc...) as developed in Damiola et
al., 2004.
To conclude, out of the 40 candidates tested, we have
identified 15 v-ErbA repressed target genes. None of these
genes were previously known to be a v-ErbA target gene.
The expression of the majority of newly identified v-ErbA 
target genes is not activated nor repressed during 
differentiation
In order to test the initial hypothesis that the erythroid
progenitors transformation by v-ErbA involves a blockade
of the differentiation process, we compared the sets of
genes obtained by SAGE analysis in this and in our previ-
ous studies [34]. We have identified 2 genes whose expres-
sion was found to be increased in T2ECs in a
differentiation state versus self-renewal state [34] and
decreased in T2ECs expressing v-ErbA versus T2ECs
expressing S61G (Figure 6A, left part). On the other hand,
we have identified 3 genes whose expression was found to
be decreased in T2ECs in a differentiation state versus self-
renewal state [34] and increased in T2ECs expressing v-
ErbA versus T2ECs expressing S61G (Figure 6A, right
part). These 5 genes may be involved both in the T2ECs
self-renewal and in the transforming process induced by
v-ErbA. Altogether, there is a very modest overlap between
these gene lists, suggesting that in majority the v-ErbA tar-
get genes might not be deregulated during differentiation,
in contrast with our expectations.
We therefore studied by real time PCR the expression of
the 15 confirmed v-ErbA target genes during the differen-
tiation process (Table 1 and see Additional File 1). We
observed that, among these v-ErbA target genes, some are
activated such as TPT1, RPS9 and RPS3a. This confirms
that differentiation related target genes can indeed be
inhibited by v-ErbA. However, we observed that the
expression of most v-ErbA target genes is either repressed
or does not vary during differentiation. These results sug-
gest other mechanisms of v-ErbA action, independent of a
mere blockade of differentiation.
T3 and RA do not activate the majority of newly identified 
v-ErbA target genes
The v-ErbA oncoprotein was initially described to be a
transcriptional repressor for genes normally activated by
T3 Receptor (T3R) and RA Receptor (RAR) [5,9]. There-
fore, we have analyzed the expression of v-ErbA target
genes by real-time PCR following a treatment by T3 and
RA (Table 1 and see Additional File 2). We observed that,
among these genes, some are activated by RAR because
their expression is induced by RA treatment in normal
cells, such as sca2, LOC129881 and eIF2B2. This confirms
that activation by RAR is indeed inhibited by v-ErbA.
However, the expression of a vast majority of newly iden-
tified v-ErbA target genes is either repressed by T3 or does
not vary in response to T3 and RA. These results suggestBMC Genomics 2007, 8:390 http://www.biomedcentral.com/1471-2164/8/390
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Real time PCR validation on multiple experiments Figure 5
Real time PCR validation on multiple experiments. The results of the real-time PCR quantification of genes repressed 
by the transforming form of v-ErbA and identified by SAGE are presented. Total RNA was extracted from the T2ECs express-
ing either the oncogenic form or the non-transforming form of v-erbA. A reverse transcription and real-time PCR analysis were 
performed to quantify the expression level of different genes. The fold repression is represented, corresponding to a decrease 
of mRNA accumulation in T2ECs expressing the transforming form of v-ErbA (VA) in comparison with T2ECs expressing the 
non-transforming form of v-ErbA (NTVA). The grey bars represent a mean of ratio calculated using three reference genes T-
Complex 1, hnRNP and ATP synthase subunit B1. The hatched bar is the mean of mRNA accumulation in the five independent 
experiments.
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that v-ErbA must also act by T3R and RAR independent
mechanisms in the transformation process.
Moreover, among the 11 differentiation target genes iden-
tified, the expression of only 3 genes is activated during
the differentiation process and repressed by v-ErbA (Table
1 Figure 6B). To conclude, most of the newly identified v-
ErbA target genes are not activated by T3, RA and differen-
tiation.
The newly identified v-ErbA target genes are cell type 
specific
The v-ErbA oncoprotein was initially demonstrated to be
a constitutive repressor of genes activated by T3 in CV-1
cells [5,6] and by T3 and RA in MCF-7 cells [9]. This sug-
gests that the new mechanisms of v-ErbA action high-
lighted in this paper could be due to the cell type in which
its action was studied. In order to determine if the newly
identified v-ErbA target genes identified in T2ECs are the
same target genes of v-ErbA as in other cells, we have com-
pared them with Chicken Embryo Fibroblasts (CEFs). v-
ErbA has been described to alter the growth control of
these cells [35]. We observed that the expression of most
newly identified v-ErbA target genes was not modulated
by v-ErbA in CEFs other than the sca2 gene (Figure 7). v-
ErbA does not have the same biological effect on different
cells (CEFs and T2ECs) and the genes deregulated under
its influence are not the same in these two cellular models.
Assessment of the v-ErbA target gene expression in response to different factors Figure 6
Assessment of the v-ErbA target gene expression in response to different factors. 6A – Comparison between the 
v-ErbA and the differentiation target genes. The Venn Diagrams represent a comparison between the list of v-ErbA repressed 
target genes (this study) and the genes upregulated during T2ECs differentiation [34] (Left part of the figure) or the list of v-
ErbA activated target genes and the genes repressed during T2ECs differentiation (Right part of the figure). 6B – Comparison 
of v-ErbA, differentiation, T3 and RA target genes. The Venn diagram summarizes the overlap in the sets of genes that were 
activated or repressed in response to v-ErbA or/and T3 or/and RA or/and during the differentiation process in T2ECs.
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These results suggest that the action of the v-ErbA onco-
protein and its target genes depend on the nature of the
host cell.
Discussion
In this paper, we identified new v-ErbA target genes. All of
these genes were found to be repressed by v-ErbA and
involved in protein metabolism and in chromatin struc-
ture/transcriptional regulation. A role for c-Myb in the
transformation process induced by v-ErbA could be one of
the indirect mechanisms of v-ErbA action. Furthermore,
this study clearly illustrates new mechanisms of v-ErbA
action, independent from T3R, RAR and erythroid differ-
entiation.
To identify the target genes of the v-ErbA oncoprotein,
previous studies have analyzed either the expression of
erythroid specific genes [12], of genes which are regulated
by T3 [10] or the expression of different membrane anti-
gens [11] in cells transformed by v-ErbA. Thus, v-ErbA has
been reported to repress the expression of only four genes:
ALA-S, Band3 [12], CAII [10] and VLA2 [11]. Repression
of Band3 and CAII by v-ErbA cannot explain altogether the
blockade of the differentiation induced by the oncogene,
since reexpression of these two proteins had little (CAII)
or no effect (Band3) on the differentiation of v-ErbA
transformed cells [15]. We searched for these four well-
established v-ErbA target genes in the two SAGE libraries
of T2ECs expressing either the oncogenic form of v-ErbA
(VA) or the non-transforming form of v-ErbA (NTVA). We
found only CAII in these libraries. Different reasons can
explain this result, including polymorphism in the tag
sequence, and a weak expression of the other genes under
these two conditions. This suggests that more v-ErbA tar-
get genes could be found by a deeper sequencing of SAGE
libraries. However, we quantified the expression of these
previously identified targets of v-ErbA by real-time PCR in
several independent experiments. Only VLA2 and Band3
are repressed by the transforming form of v-ErbA com-
pared to the non-transforming one (data not shown).
These results suggest that these genes could be indeed
involved in the transformation process induced by v-ErbA
as previously suggested for Band3 and VLA2 [11,15]. Thus,
the identity of cellular genes whose deregulation by the v-
erbA  oncogene is responsible for the transformation
remained an open question. By using a global approach
by SAGE, we compared the transcriptome of T2ECs
expressing the oncogenic form of v-ErbA with the tran-
scriptome of T2ECs expressing the non-transforming form
of v-ErbA (S61G). This allowed us to identify several new
v-ErbA target genes potentially involved in the transfor-
mation induced by the oncogene. The vast majority of
expressed genes were not differentially expressed between
the two conditions, suggesting that the switch from a nor-
mal state toward a pathological state involves a very lim-
ited number of genes and small variations.
The newly identified v-ErbA target genes can be either pri-
mary or secondary consequences of v-ErbA action. Indeed,
v-ErbA target genes involved in the transformation proc-
ess cannot be differentiated from genes whose expression
is modulated consequently to the transformation process.
The study of the biological function of each v-ErbA target
gene could answer in part this question. Moreover,
Genome wide Chromatin Immunoprecipitation (ChIP)
assay could be performed to determine the amount of tar-
Table 1: Expression of the v-ErbA target genes in T2ECs during the differentiation process or following a T3, RA or T3 and RA 
treatment.
Genes Differentiation T3 RA T3+RA
Sca2 - - 0 + + + +
LOC129881 - - 0 + 0
eIF2B2 - 0 + +
R N F 1 3 -000
TGF-β1-  - - 0 -
β-Actin - - 0 0 0
TPT1 + 0 0 0
R P S 3 0000
N A P 1 L 1 -000
R P S 9 +000
R P S 3 a +000
eEF1α1 0 * 000
R P L 1 3 0000
M G C 8 3 9 6 9 0000
H M G 1 7 -000
Expression levels of v-ErbA target genes, quantified by real-time PCR, were classified into three groups as follows: (++) strong activation, (+) 
moderate activation, (0) no variation, (-) repression and (--) strong repression by the different treatments. The table is the synthesis of the results 
obtained. For actual values and conditions used – see supplementary data. We used, as the reference gene for this experiment, eEF1α1* in 
agreement with Damiola et al., 2004.BMC Genomics 2007, 8:390 http://www.biomedcentral.com/1471-2164/8/390
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get genes that are susceptible to be under the direct influ-
ence of v-ErbA. Among the four previously established
target genes of v-ErbA, only CAII was demonstrated to be
a primary target of v-ErbA [13,20]. The molecular mecha-
nisms through which ALA-S, Band3 and  VLA2  are
repressed by v-ErbA remain elusive.
The bioinformatic analysis of the v-ErbA target gene pro-
moter sequences revealed the presence of c-Myb binding
sites as a motif that appears more frequently in the pro-
moters of v-ErbA repressed target genes. We observed that
v-ErbA upregulates c-Myb expression and that the level of
c-myb expression was equivalent in cells expressing either
wild-type or S61G forms of v-ErbA, as previously demon-
strated by Bauer et al. [14]. Since the non-transforming
form of v-ErbA also induces c-Myb upregulation, this does
not seem to be sufficient per se to induce the transforma-
tion process. In contrast, reporter gene experiments with a
plasmid containing c-Myb binding sites upstream the
luciferase gene suggest that v-ErbA, in contrast to S61G,
could activate c-Myb by either direct or indirect interac-
tions which will lead to the repression of a subset of key
genes. These data propose that a functional interaction
with c-Myb could play a role in the transforming process
induced by v-ErbA. The c-myb proto-oncogene encodes a
transcription factor that functions as an activator as well as
Expression of the v-ErbA target genes identified in T2ECs, in CEFs expressing v-ErbA or the S61G form of v-ErbA Figure 7
Expression of the v-ErbA target genes identified in T2ECs, in CEFs expressing v-ErbA or the S61G form of v-
ErbA. Total RNA was extracted from CEFs expressing either the oncogenic form or the non-transforming form of v-erbA. A 
reverse transcription and real-time PCR analysis were performed to quantify the expression level of genes, which are 
repressed by v-ErbA in T2ECs. The fold variation is represented as VA/NTVA ratio and corresponds to a decrease or an 
increase of the different mRNA in CEFs expressing the transforming form of v-ErbA (VA) in comparison with CEFs expressing 
the non-transforming form of v-ErbA (NTVA). The results were normalized using four reference genes T-Complex 1, hnRNP, 
ATP synthase subunit B1 and GAPDH, and correspond to the mean with standard deviation of four to five independent experi-
ments. This figure presents the results of the expression level quantification of most v-ErbA target genes, except for 
MGC83969 gene that could not be amplified.
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a repressor of transcription and appears to play a critical
role in the regulation of hematopoietic cell differentiation
[36]. Its transcription is typically down-regulated during
the erythroid cell maturation process [37] and constitutive
expression of c-myb blocks erythroid differentiation [38].
It has been proposed that v-ErbA represses at least a subset
of genes that are normally upregulated by T3 and/or RA
and that are possibly linked to the differentiation program
of the cell [5,9]. However, our results suggest that v-ErbA
could modulate the transcription of a third group of genes
that are not under the control of RAR or T3R, or not
affected by the differentiation process. The evidence that
all TR target genes are not necessary v-ErbA target genes is
also supported by DNA binding specificity studies
strengthened by functional assays [23,24]. The evidence
that some RAR target genes are not v-ErbA target genes is
also reinforced by experiments using different retinoic
acid response elements and seems to depend upon the cell
type tested [9,39-41]. The v-erbA oncogene has accumu-
lated mutations that could have created a v-ErbA specific
subset of target genes with some TR target genes, some
RAR target genes and possibly some target genes for other
transcription factors. This could lead to the specific repres-
sion of a subset of relevant key genes.
The protein synthesis function is one of the most promi-
nent category of v-ErbA deregulated genes, and one of the
most unexpected. We observed a reduction in the expres-
sion of several genes encoding proteins involved in pro-
tein synthesis, suggesting an important role of variations
in translation during transformation. However, the
expression of all proteins involved in translation, in par-
ticularly ribosomal proteins, is not affected by v-ErbA. It is
therefore unlikely that a global change in the amount of
ribosomes might result from v-ErbA action. In support of
this, several studies have suggested an extraribosomal
function of at least some ribosomal proteins [42]. Inter-
estingly, ribosomal proteins, translation initiation and
elongation factors have been found to play roles in regu-
lating cell growth and transformation due to such extrari-
bosomal activities [42]. One should also note that
variation in the amount of mRNA encoding ribosomal
proteins has already been observed to be a common fea-
ture in large scale transcriptomic analysis ([43] and refer-
ences therein).
Altogether, this paper suggests the involvement of a
wealth of new unanticipated and possibly indirect mech-
anisms of v-ErbA action, independently of T3R, RAR and
differentiation. The function of the deregulated genes is
currently under study in our laboratory.
Methods
Cell culture
TGF-β1 and TGF-α were purchased from PeproTech as a
lyophilized human recombinant protein and resus-
pended as previously described [17].
All-trans Retinoic acid was purchased from SIGMA, pre-
pared as a 10-3 M solution in ethanol and subsequently
diluted in α-MEM.
3,3',5-Triiodo-L-thyronine (Triiodothyronine) was pur-
chased from SIGMA, prepared as a 10-3 M solution in 0,1N
NaOH and subsequently diluted in α-MEM.
T2ECs were generated from SPAFAS white leghorn chick-
ens (PA12 line from INRA, Tours, France) as previously
described [17]. These cells were expanded in LMI medium
(α-MEM medium, 10% FBS (Fetal Bovine Serum), 10-3 M
Hepes, 10-4 M β-mercaptoethanol, 10-6 M dexamethasone,
5 ng/ml TGF-α, 1 ng/ml TGF-β1, penicillin and strepto-
mycin (100 U/ml)).
Differentiating cells were obtained by changing the
medium of exponentially growing cells into DM17
medium (α-MEM medium, 10% FBS (Fetal Bovine
Serum), 10-3 M Hepes, 10-4 M β-mercaptoethanol, penicil-
lin and streptomycin (100 U/ml), 15% ACS (anemic
chicken serum), 10 ng/ml of insulin) [17]. ACS was pre-
pared as previously described [41].
Chicken Embryo Fibroblasts (CEFs) were generated from
SPAFAS white leghorn chickens (LD1 line from INRA,
Tours, France) as previously described [44]. These cells
were expanded in growth medium (Ham's F10 medium,
TPB, 5% FBS, 1% NCS (Normal Chicken Serum), 0,1%
Sodium Bicarbonate, penicillin and streptomycin (100 U/
ml) and 2,5 µg/ml Amphotericin B).
Viral infections
Viruses were produced by cotransfection of pXJ12 [35] or
pS61G [9] with pRAV-1 plasmid on CEFs. pXJ12 coex-
presses the Neor gene and the v-erbA oncogene [45] and
pS61G coexpresses the Neor gene and a mutant version of
v-erbA oncogene [9]. CEFs were infected with viral super-
natant XJ12 and S61G previously obtained from CEFs
transfected, selected in growth medium containing 0,4
mg/ml G418 (Gibco) for 4 days and then expanded in
growth medium.
T2ECs were infected with viral supernatant obtained from
CEFs infected and selected for 5 days in the presence of 3
mg/ml G418. The infected cells were purified by centrifu-
gation through a density gradient on Lymphocytes Sepa-
ration Medium (Eurobio) to get rid of dead cells and
debris, and seeded in LMI medium.BMC Genomics 2007, 8:390 http://www.biomedcentral.com/1471-2164/8/390
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SAGE libraries generation and data analysis
RNA extraction and reverse transcription assay were per-
formed as previously described [41].
We prepared RNA samples from T2ECs infected with XJ12
(VA) or infected with S61G (NTVA). Both cultures were
originated from the same cell preparation and divided just
before the infection of cells. The infection was validated
by PCR verification of v-erbA mRNA, and verification of
the presence of the mutation S61G before proceeding
with the construction of the libraries (data not shown).
SAGE library construction was performed with 10 µg of
total RNA, using the I-SAGE™ kit (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer's protocol. New
PCR primers were redesigned for verification steps on
chicken mRNAs. cDNA synthesis verification was per-
formed using chicken Cyclin D1 primers (5'-ACGCTCAG-
GGACTATACAGG-3' and 5'-GTCTGATGGAGTTGTCGG-
3'; AT = 62°C) and chicken Cyclin D2 primers (5'-
GTGCTAGTAAGCAACCTTAGGC-3' and 5'-
GAACAAGCCTGACTTTCTGTGC-3'; AT = 55°C). NlaIII
digestion verification was performed using chicken Cyclin
D1 primers and chicken c-rel primers (5'-CTGCTCGAAT-
TCAAGCTTCT-3' and 5'-CCAGTTCTTTAATTACCAAACC-
3'; AT = 55°C). Linker ligation and BsmFI digestion verifi-
cation was performed using the DTP-1 and DTP-2 primers
provided with the I-SAGE™ kit together with one Cyclin
D2 primer. Concatemer clone sequencing was performed
by Genome Express (Meylan, France) and by the Geno-
scope (Evry, France). Tags were extracted from concatemer
sequences by using the R package Sagenhaft [46]. The
occurrence number of each tag was computed by taking
into account the sequencing errors in concatemer
sequences (estimated by the Phred quality score for each
base), by using the modelling described in Beissbarth et
al., 2004.
Tag identification was performed using Identitag [19] and
chicken transcript sequences from the TIGR Gene Index
release 10 and from the Refseq databank.
In order to assess the significance of the differential
expression of tags between the two libraries, we imple-
mented the Z-test [47] using the R language. We adjusted
the resulting p-values for multiple testing by using the
method proposed by Benjamini and Hochberg [48] and
implemented in the Bioconductor R package multtest.
Because the completion of annotation is higher for
human genes than for chicken ones, the classification into
functional groups is based on the annotation of human
genes orthologous to chicken differentially expressed
genes. The classification was made with the DAVID soft-
ware [49].
Real-time PCR
Real-Time PCR was performed with a LightCycler system
(Roche) or MX3000P Stratagene using the LightCycler
FastStart DNA Master SYBR Green I (Roche) according to
the manufacturer's instructions. Primer design was carried
out using the Primer3 software system [50]. In order to
assess the quality and the efficiency of the RT reactions, we
analysed the expression of different invariant genes,
namely  T-Complex1  (Sigenae accession number:
BBSRC60295473F1.1.3.1),  hnRNP  (Sigenae accession
number: AB038230.1.3.153), ATP Synthase subunit B1
(GenBank accession number: XM_417993.1),  GAPDH
(GenBank accession number: K01458) and eEF1α1 (Gen-
Bank accession number: NM_204157.2) (only in differen-
tiation experiments) as internal standards. In order to
quantify gene expression, standard curves were generated,
for each pair of primers, by dilution series of a sample. The
relative expression ratio (R) for each target gene was per-
formed using a previously published mathematical
method [51]:
ratio = (Etarget) ∆CP target(control - sample)/(Eref) ∆CP ref(control - sam-
ple)
The reference gene is a house-keeping gene transcript. For
the target gene and the reference gene, E is the real time
PCR efficiency and ∆CP is the crossing point deviation of
control versus sample. Real time PCR efficiencies were cal-
culated according to E = 10(-1/slope). For information about
the specific PCR conditions and primers sequences used,
please contact the authors.
Western Blot Analysis
Cells were harvested and washed in cold PBS supple-
mented with 1% phosphatase inhibitor cocktail 2 (Sigma)
and complete mini EDTA-free protease inhibitor cocktail
(Roche). The protein concentration was determined by
using the Dc protein Assay (BioRad). Cells were then lysed
in Laemmli buffer (0,125 M Tris pH6,8, 2% SDS, 10%
glycerol, 5% β-mercaptoethanol and 0,1% bromophenol
blue) following 5 min at 100°C. 30 µg of proteins were
analyzed in a sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) (12,5% acrylamide) and
blotted on Protean BA85 nitrocellulose membrane. After
blockage in 0,1% tween-20 tris-buffered saline (TBS) 5%
nonfat milk during 1 hour at room temperature, the
membrane was probed with primary antibodies (dilution
1/200 in TBS-0,1%Tween-5% nonfat milk for c-Myb anti-
body (M-19, Santa Cruz) with an incubation of 4 hours at
room temperature; dilution 1/30000 in TBS-0,1%Tween-
5% BSA for GAPDH antibody (14C10, Cell signaling)
with an incubation of 1 hour at room temperature). The
membranes were washed twice in TBS-0,1%Tween before
incubation during 1 hour at room temperature with a
horseradish-peroxidase-coupled secondary anti-rabbitBMC Genomics 2007, 8:390 http://www.biomedcentral.com/1471-2164/8/390
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IgG antibody (dilution 1/7000 in TBS-0,1%Tween-5%
nonfat milk for c-Myb analysis or in TBS-0,1%Tween-5%
BSA for GAPDH analysis). Proteins were detected using
the ECL plus western blotting detection system (Amer-
sham).
Promoter sequence analysis
The WASHUC1 chicken genome assembly was down-
loaded from the Ensembl ftp site [52] as of September
2006. Transcripts were aligned on the chicken genome
using the BLAT algorithm [53]. The most 5' position of
this alignment was used as a putative transcription start
site (TSS). 3 kbp 5' of the TSS and 1 kbp 3' of the TSS were
extracted and stored as promoter regions. This gave us two
sets of promoters: 31 sequences from genes that appeared
as being repressed by v-ErbA by SAGE and 21 sequences
from genes that appeared as being activated by v-ErbA. We
then applied on those two sets of sequences an original
algorithm called FAVST (Finite Automata-based VST con-
struction) [27]. Marguerite, an implementation of an
extended FAVST algorithm will be described elsewhere
(Mitasiunaité, I. et al., in preparation; see also [54]). In
contrast with other motif-searching algorithm, Marguerite
does not try to find statistically overrepresented motifs, as
compared to a random distribution. Marguerite is an exact
algorithm that searches exhaustively for regular expres-
sion-type patterns that are over-represented in a given set
of sequences (positive set) and under-represented in a dif-
ferent but related set of sequences (negative set) without
any a priori about these patterns excepted their minimal
length. Three parameters are required for running Margue-
rite: the minimum length of the pattern, the maximum
number of examples in the negative set, and the mini-
mum number of examples in the positive set (see legend
to figure 2). The identification of the putative transcrip-
tion factor binding motifs found was done using the
PATCH function of the commercial version of TRANSFAC
[55].
Transcriptional activation assay
Transient transfections were performed by nucleofection
method (Amaxa Technology). For each nucleofection
assay, 10 × 106 cells were resuspended in 100 µl of nucle-
ofector buffer (Cell line Nucleofector kit V, reference VCA-
1003; Amaxa Biosciences) and nucleofected with the T-16
program. The β-galactosidase expressing plasmid (pCMV-
β-Gal; 0,5 µg), luc reporter plasmids containing either five
wild-type (polyA-EW5-LUC; 5 µg) or mutant (poly-A-
EM5-LUC; 5 µg) Myb binding sites [29], basic pGL2 (5 µg;
Promega), pXJ12 expressing the v-erbA oncogene (VA; 5
µg) [35,45] and pS61G expressing a mutant version of v-
erbA (NTVA; 5 µg) [9,18] were transfected into T2ECs.
Twenty-four hours after transfection, the cells were
assayed for luciferase activity (Bright-Glo™ Luciferase
Assay system; Promega) and β-Gal activity (Gal-screen®
System; Applied Biosystems). All transfections were per-
formed two to three times and the pCMV-β-Gal control
was used to normalize the transfection experiments. Rela-
tive luciferase activities were obtained.
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